FIT Biotech Oy
Company release 27.4.2018 at 11:00 AM EET
APPOINTMENT OF TOMMI HOLOPAINEN AS CFO AND AS A MEMBER OF THE MANAGEMENT TEAM OF FIT BIOTECH
Tommi Holopainen, MSc Economics, EMBA, has been appointed as a new CFO and a member of the management team of FIT Biotech. He will start in the new position at the latest on 1.8.2018.
Tommi Holopainen has had a long career in diverse international managerial positions at Telia Company since 1995. He has held the post of CFO at Telia Sweden and Telia Nepal and headed the unit of Business Development in Sweden and Russia. At Telia, Mr. Holopainen has also been responsible for purchases for the Eurasian region as well as for product management and strategy processes in Finland.
CEO Erkki Pekkarinen comments:
"Tommi Holopainen is a professional with strong experience in developing financial management and international business. Tommi will be an excellent person in strengthening our team. Our aim is to licence our drug candidates to partners who have the required knowledge to carry out clinical research, marketing authorisation applications and commercialisation of the drugs. I warmly welcome Tommi to make FIT Biotech an even stronger forerunner and leader in the biotech industry when it comes to the development of treatments based on biological drugs."
"At the same time, I sincerely thank our interim CFO Kaisa Kokkonen for her excellent contribution to the development of our company's corporate governance."
The position of CFO had been outsourced to Kaisa Kokkonen from Akeba Oy. She will serve as interim CFO until the end of June 2018 replacing Liisa Laitinen during her long-term absence. Liisa Laitinen retired as of 1st of February 2018.
FIT BIOTECH OY
For further information:
CEO Erkki Pekkarinen
Tel.: +358 44 027 0080
E-mail: erkki.pekkarinen@fitbiotech.com
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licences its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines. FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.